Name
GS3-02 - Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link